Mr. David Ben-Ami is an Independent External Director at Novolog (Pharm UP 1966) Ltd., a General Partner at SBI JI Innovation Advisory Ltd., a Managing Partner at Corundum Open Innovation Ltd. and an Executive Investment Director at SBI Japan-Israel Innovation Fund.
He is on the Board of Directors at ImmunoBrain Checkpoint Ltd., Novolog (Pharm UP 1966) Ltd., ConTIPI Medical Ltd., Joy Ventures and Quark Pharmaceuticals, Inc. Mr. Ben-Ami was previously employed as an Independent Director by BioMilk Ltd., a Chief Executive Officer by NVR Labs, Inc., a Director-Business Development by Teva Medical Ltd., a Director-Business Development by Teva Naot Ltd., and a Director-Business Development by Teva North America.
He also served on the board at Chemomab Ltd., Entera Bio Ltd., Degania Silicone Ltd., Macrocure Ltd., V.V.T. Med Ltd., Boston Scientific Israel Ltd., Boston Scientific Corp., ElectReon Wireless Ltd., Hairstetics Ltd., Meytav Technological Enterprises Innovation Center Ltd., Nanothera Ltd., Novolog Ltd., Ovalum Ltd. and VVT Medical Ltd.
He received his undergraduate degree from Tel-Aviv University and an MBA from Tel-Aviv University.